Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 9 498 / https://doi.org/10.3332/ecancer.2015.498

Policy

PACE Continuous Innovation Indicators—a novel tool to measure progress in cancer treatments

Concerns about rising health care costs and the often incremental nature of improvements in health outcomes continue to fuel intense debates about ‘progress’ and ‘value’ in cancer research. In times of tightening fiscal constraints, it is increasingly important for patients and their representatives to define what constitutes ’value’ to them. It is clear that diverse stakeholders have different priorities. Harmonisation of values may be neither possible nor desirable. Stakeholders lack tools to visualise or otherwise express these differences and to track progress in cancer treatments based on variable sets of values.

The Patient Access to Cancer care Excellence (PACE) Continuous Innovation Indicators are novel, scientifically rigorous progress trackers that employ a three-step process to quantify progress in cancer treatments: 1) mine the literature to determine the strength of the evidence supporting each treatment; 2) allow users to weight the analysis according to their priorities and values; and 3) calculate Evidence Scores (E-Scores), a novel measure to track progress, based on the strength of the evidence weighted by the assigned value.

We herein introduce a novel, flexible value model, show how the values from the model can be used to weight the evidence from the scientific literature to obtain E-Scores, and illustrate how assigning different values to new treatments influences the E-Scores.

The Indicators allow users to learn how differing values lead to differing assessments of progress in cancer research and to check whether current incentives for innovation are aligned with their value model. By comparing E-Scores generated by this tool, users are able to visualise the relative pace of innovation across areas of cancer research and how stepwise innovation can contribute to substantial progress against cancer over time. Learning from experience and mapping current unmet needs will help to support a broad audience of stakeholders in their efforts to accelerate and maximise progress against cancer.

Keywords: cancer, innovation, value, indicators, progress

Loading Article Metrics ... Please wait

Author interviews

Gordon McVie

European Institute of Oncology, Milan, Italy and Founding Editor of ecancer.org

Related videos

Related articles

Special Issue: Building a comprehensive cancer survivorship program

Abstract | Full Article | PDF Published: 12 Dec 2019 / https://doi.org/10.3332/ecancer.2019.992

Special Issue: Evaluation of a charity-led secondary breast cancer support day: a model of survivorship care

Abstract | Full Article | PDF Published: 12 Dec 2019 / https://doi.org/10.3332/ecancer.2019.991

Special Issue: Recruiting cancer survivors into research studies using online methods: a secondary analysis from an international cancer survivorship cohort study

Abstract | Full Article | PDF Published: 12 Dec 2019 / https://doi.org/10.3332/ecancer.2019.990

Special Issue: The experiences of giving and receiving social support for men with localised prostate cancer and their partners

Abstract | Full Article | PDF Published: 12 Dec 2019 / https://doi.org/10.3332/ecancer.2019.989

Special Issue: A systematic review of laser therapy for vulvovaginal atrophy/genitourinary syndrome of menopause in breast cancer survivors

Abstract | Full Article | PDF Published: 12 Dec 2019 / https://doi.org/10.3332/ecancer.2019.988



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation